CBD Shows Promise in Lab But Fails to Beat Placebo for Cocaine Addiction | Research

The takeaway

Despite promising preclinical results, a scoping review found that clinical trials of CBD for cocaine use disorder showed no significant benefit over placebo for craving, relapse, or cognitive function.

Addiction researchers, clinicians treating stimulant use disorders, and anyone interested in the limits of CBD therapeutic claims.

What the researchers found

Clinical studies did not demonstrate significant efficacy of CBD over placebo in reducing cocaine craving, preventing relapse, or improving cognitive performance. However, CBD was well tolerated and had fewer adverse events than conventional treatments. The gap between preclinical promise and clinical reality highlights methodological challenges.

Why it matters

This is a cautionary tale for translating preclinical cannabis research: what works in animal models doesn't always work in humans. Cocaine addiction desperately needs new treatments, and while CBD's safety profile is encouraging, its efficacy remains unproven.

The numbers in context

CBD was well tolerated across all clinical trials. No significant efficacy over placebo for: cocaine craving, relapse prevention, cognitive performance. Key limitations: variability in dosage, treatment duration, and study design across trials.

How the study worked

Scoping review synthesizing clinical trial evidence on CBD for cocaine use disorder. Evaluated effects on craving reduction, relapse prevention, cognitive function, and emotional regulation. Assessed methodological quality and identified research gaps.

What this study cannot tell us

Scoping review (not systematic with meta-analysis). Small number of clinical trials available. Heterogeneous dosing and study designs make comparison difficult. Short treatment durations may miss delayed effects.

How to read the evidence

Scoping review of clinical trials showing consistent null results — informative negative finding with implications for research direction.

When this study was published

Published in 2026, providing an updated assessment of CBD for cocaine addiction.

The bigger picture

This negative finding is actually valuable — it prevents false hope and redirects research toward potentially more effective approaches, such as combining CBD with behavioral therapy or other medications rather than using it as a standalone treatment.

Questions still open

Would higher or longer CBD dosing help? Could CBD work better as part of a multimodal treatment? Are there specific subgroups of cocaine users who might respond to CBD?

Common questions

Can CBD treat cocaine addiction?

Current evidence says no — clinical trials found CBD was no better than placebo for reducing cocaine cravings or preventing relapse, despite promising results in animal studies. It may have potential as part of combination therapy, but not as a standalone treatment.

Why does CBD work in animals but not humans for cocaine addiction?

The gap likely reflects differences in dosing, timing, and the complexity of human addiction. Animal models can't capture social, psychological, and environmental factors that drive human drug use.

Read the original research

Cannabidiol as a treatment for cocaine use disorder: a scoping review.

Naunyn-Schmiedeberg's archives of pharmacology

View on PubMed ↗Publisher’s paper ↗

Citation

Dos Santos, Leticia Custódio; da Cunha, Verônica Barros; Ribeiro, Jéssyca Milene; Torres, Larissa Helena Lobo; Garcia, Raphael Caio Tamborelli. (2026). Cannabidiol as a treatment for cocaine use disorder: a scoping review.. Naunyn-Schmiedeberg's archives of pharmacology. https://doi.org/10.1007/s00210-026-05037-x